Cancer screening in RA - retrospective, matched cohort study of 1,614 RA vs 1,597 controls (mean 63 yrs); @ 5 yrs, RA had less cervical cancer screens (52% vs 58%) (aHR:0.83); but no decrease in screens for breast (aHR:0.98), prostate (aHR:0.99), or colorectal (aHR:1.04) CA https://t.co/NnxRnZcZwq

"FLAME" - machine learning model developed to predict SLE flares. Data from 28,433 SLE pts (2011-2022) looked at clinical & social determinants of health (SDoH) to predict 3 mo flare risk. AUROC = 0.67; SHAP analysis identified HA, OBS, & pyuria as predictors. Is this the https://t.co/6Eqqc9w2oV

PsA is worse in women--why? 100 PsA pts, serum study of differentially expressed proteins - 20 times more sex-specific DEPs in PsA males than females (PsA vs controls). In women leukotriene A-4; and in men IL-36, NEK7 & PIK3CA/PIK3R1 were significant predictors. https://t.co/JzI1n6Hf5G

CKD & Osteoporosis Rx Revisited (7.25.2025) Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow. https://t.co/k78DRpWIJS https://t.co/aYKvIhmJN1

Heart Attack No Longer the Leading Cause of Death in America . Journal of AHA reports that heart disease mortality in the United States dropped by 66 percent over the past five decades, driven largely by a dramatic decline in fatal heart attacks. https://t.co/whMQSMozVv https://t.co/ik6uydmspF

Systemic immune-inflammation index (SII), as a potential biomarker -- computed as platelet count × neutrophil count/lymphocyte count. SII has been shown to be useful in RA, PsA, SpA, SLE and vasculitis, reflecting disease activity, drug responses & supplements ESR & CRP levels https://t.co/LuFaYbWiWN

Review of risankizumab efficacy & safety included 545 psoriasis pts showing Mean PASI decreased from 14 to 0.5 at 208Wk. PASI100 achieved in 33% and 74% at 16Wk & 208Wk. Bio-naïve responded faster bio-experienced pts - only 5 pts D/C for adverse events https://t.co/VklLWpD0SF https://t.co/zZfuiFijd4

MTX or TNFi use in elderly #RA pts w/in a year of Dx of melanoma was not associated with increased mortality. This included melanoma in situ (48%), localized (47%) and regional (5%) melanoma. Steroid use however was assoc w/ reduced survival. https://t.co/QOXfEf51S1 https://t.co/6BPtEV6sOU

FDA is evaluating the safety of Vyvgart Hytrulo, ((efgartigimod) used to treat AChR Ab positive generalized myasthenia gravis (gMG). But in clinical trials there are reports of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)” https://t.co/6GBwIJ4ig4

Osteoporosis Drug May Lower Osteoarthritis Risk A target trial emulation study using administrative claims suggests that romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis. https://t.co/fWWw2t2jzR

PMR & GCA not assoc w/ increased mortality, Norway study of 274 isolated PMR (mean age 72 yrs) & 63 GCA (age 72 yrs) pts. After mean F/U 13.7 yrs 96% were deceased. Standardized mortality ratio was Not incr for PMR (0.97)or GCA (1.10), but men w/ PMR had , lower all-cause https://t.co/03lNpQiVYZ